N/A
N=18
The Effect of Growth Hormone Replacement on Liver Fat
Growth Hormone, Recombinant · Fatty Liver
Bottom Line
View on ClinicalTrials.gov: NCT00774579 ↗Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Jul 2019
Primary outcome: Primary: Intrahepatocellular Lipid (IHCL) Content — -0.63; 0.11 % change from baseline — p=0.6
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 20+ yrs
- Sex
- All
- Sponsor
- Imperial College London
- Primary completion
- Mar 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Intrahepatocellular Lipid (IHCL) Content |
-0.63; 0.11 | 0.6 |
| SECONDARY Total Adipose Tissue |
-1.8; 0.24 | 0.1 |
Summary
We will examine a cohort of growth hormone deficient adults starting growth hormone (GH) replacement. The purpose of this study is to determine whether GH replacement reduces the fat content of the liver.
To compare the results we will include growth hormone deficient patients who do not start GH replacement as controls.
Eligibility Criteria
Inclusion Criteria
- 20-70 years of age
- Growth hormone deficiency, with (cohort 1) or without (cohort 2) planned growth hormone (GH) replacement
- clinically stable
Exclusion Criteria
- known hepatic disease
- Acromegaly
- Diabetes mellitus
- growth hormone replacement within the last 12 months
- cushing's disease, if not cured for at least 12 months
- any contraindication to MR studies as set out in the MR safety questionnaire
Data sourced from ClinicalTrials.gov (NCT00774579). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.